Skip to main content
. 2020 Nov 26;15(30):2933–2953. doi: 10.2217/nnm-2020-0344

Figure 7. . MIF is a valid target for the inhibition of PA01 attachment to human airway epithelial cells.

Figure 7. 

(A) Recombinant migration inhibitory factor enhances attachment of PA01 to A549 epithelial cells. (B) SCD-19 (100 μM) significantly decreases attachment of PA01 to A549 epithelial cells. (C) SCD-19 PLGA nanoparticles (NPs) (100 μM) inhibits attachment of PA01 to A549 epithelial cells. (D) PLGA-SCD-19 NPs (100 μM) inhibits attachment of PA01 to 16HBE14o- epithelial cells. (E) PLGA SCD-19 NPs (100 μM) inhibits attachment of PA01 to CFBE410- epithelial cells. PLGA-SCD-19 NPs (100 μM) inhibit attachment of clinically isolated P. aeruginosa to (F) 16HBE14o- and (G) CFBE410- epithelial cell monolayers. Data are presented as mean ± SEM of three replicates from three independent experiments. (A) A One-way ANOVA with a Tukey's multiple comparison post-hoc test was used to test for statistical differences; **p < 0.01 medium compared with 100 ng/ml migration inhibitory factor. (B–F) A two-tailed unpaired t test was used to test for statistical significance; *p < 0.05; **p < 0.01; ***p < 0.001.

PLGA: Poly lactic-co-glycolic acid.